Eurostars is part of the European Partnership on Innovative SMEs. The partnership is co-funded by the European Union through Horizon Europe.
Funding supports international R&D led by Epigenica with MTG Research and Development Lab and AD-ABC (Algarve Biomedical Center)
STOCKHOLM, Sweden, September 8th, 2025 – Epigenica AB has been awarded a Eurostars grant of 5 million SEK to run a 30-month international R&D project , called NUPLEX, starting on October 1st, 2025. NUPLEX will develop, pilot, and demonstrate Epigenica’s proprietary technology for highly multiplexed epigenomic profiling of circulating nucleosomes, enabling AI-powered cancer diagnostics.
The project is led by Epigenica AB (Sweden), which develops epigenetic screening solutions based on their proprietary EpiFinder platform. MTG Research and Development Lab (Portugal) contributes expertise in AI, federated learning and data infrastructure. AD-ABC, Algarve Biomedical Center (Portugal), provides clinical expertise, patient cohorts, and validation in relevant settings.
“We are very excited about receiving this Eurostars grant and to collaborate with two highly skilled partners. Their expertise in AI-driven analytics and clinical oncology perfectly complements the project need, and together we will demonstrate the full potential of our technology for multi-cancer detection,” said Mohamad Takwa, CEO of Epigenica.
Detection of cancer is one of the most pressing challenges in global healthcare. Current liquid biopsy methods are limited by sensitivity and cost. Our technology can screen multiple patients for multiple cancers in a single assay, providing rich epigenomic data combined with AI-based classification to enable more scalable and cost-effective cancer detection. Epigenetic alterations are frequent across diverse cancer types and are both biomarkers for early detection and targets for therapy, positioning epigenetics as a critical frontier in future cancer diagnostics and treatment.
Eurostars is a Eureka Network programme that funds collaborative R&D led by innovative SMEs, co-financed by participating countries and the EU through Horizon Europe. Epigenica is the lead organisation in the consortium, and the project will run for 30 months starting October 1st, 2025.
About Epigenica
Epigenica is a life sciences technology company advancing high-throughput epigenetic solutions for research, diagnostics, and drug development. The company’s proprietary EpiFinder platform enables simultaneous analysis of multiple epigenetic markers across many samples with high resolution, efficiency, and affordability. Epigenica offers a broad product portfolio to support diverse applications in oncology, pharmaceutical development, and longevity. Powered by Epigenica’s patented high-throughput, multiplex, quantitative ChIP-seq technology (hmqChIP), the platform provides scalable, cost-effective epigenenomic profiling using various starting materials. Epigenica is helping customers generate actionable insights to advance multi-omics and translational research, enable biomarker discovery, and accelerate next-generation sequencing (NGS) applications to improve human health.
Corporate
Epigenica CEO Mohamad Takwa, Ph.D.
mt@epigenica.se
For media
+46 8 36 53 93
